NEW: Find great deals on the latest gadgets and more in the ScienceDaily Store!
Science News
from research organizations

Cystic Fibrosis Testing: Next Steps

April 27, 2009
American Journal of Pathology
Three reports describing advances in cystic fibrosis genetic testing appear in the latest issue of The Journal of Molecular Diagnostics.

Three reports describing advances in cystic fibrosis genetic testing appear in The Journal of Molecular Diagnostics.

Cystic fibrosis is a hereditary disease that affects mucus secretions in the lungs, liver, pancreas, and intestines. Approximately 1 in 4000 children born in the United States is affected with cystic fibrosis. Cystic fibrosis is an autosomal recessive disease caused by mutations in the CFTR gene; cystic fibrosis patients must inherit a mutated gene from each parent.

Genetic screening for cystic fibrosis carrier mutations (one copy of a mutated gene) is universally recommended for the reproductive-age population. Current professional guidelines call for screening a panel of 23 common mutations in CFTR; however, many laboratories screen for an expanded panel of mutations. In the May 2009 issue of The Journal of Molecular Diagnostics, three articles describe improvements in cystic fibrosis genetic screening.

In one article, Pratt et al describes a project coordinated by the Centers for Disease Control and Prevention's Genetic Testing Reference Material (GeT-RM) Program to develop a set of reference materials for the expanded cystic fibrosis panel of mutations. The public availability of these materials will help to ensure the accuracy of cystic fibrosis genetic testing. The reports by Schwartz et al and Hantash et al identify mutations that may lead to false screening results, either due to a large deletion in CFTR or because of mutations that interfere with laboratory screening methods.

Wayne Grody, of the UCLA School of Medicine, Los Angeles, CA, who is not affiliated with these studies, states "Taken together, these three papers demonstrate how the widespread and thoughtful experience with [cystic fibrosis] mutation testing and screening continues to reveal new insights about the mutational alleles of the CFTR gene and further refinements in how best to detect them and assure appropriate quality control while doing so."

Story Source:

Materials provided by American Journal of Pathology. Note: Content may be edited for style and length.

Journal References:

  1. Hantash FM, Rebuyon A, Peng M, Redman JB, Sun W, Strom CM. Apparent homozygosity of a novel frame shift mutation in the CFTRA gene because of a large deletion. J Mol Diagn, 2009, 253-256
  2. Pratt et al. Development of Genomic Reference Materials for Cystic Fibrosis Genetic Testing. Journal of Molecular Diagnostics, 2009; 11 (3): 186 DOI: 10.2353/jmoldx.2009.080149
  3. Schwartz KM, Pike-Buchanan LL, Muralidharan K, Redman JB, Wilson JA, Jarvis M, Cura MG, Pratt VM. Identification of cystic fibrosis (CF) variants by PCR/oligonucleotide ligation (OLA) assay. J Mol Diagn, 2009, 211-215
  4. Grody et al. Cystic Fibrosis Testing Comes of Age. Journal of Molecular Diagnostics, 2009; 11 (3): 173 DOI: 10.2353/jmoldx.2009.090024

Cite This Page:

American Journal of Pathology. "Cystic Fibrosis Testing: Next Steps." ScienceDaily. ScienceDaily, 27 April 2009. <>.
American Journal of Pathology. (2009, April 27). Cystic Fibrosis Testing: Next Steps. ScienceDaily. Retrieved February 28, 2017 from
American Journal of Pathology. "Cystic Fibrosis Testing: Next Steps." ScienceDaily. (accessed February 28, 2017).